Ahmed Nadeem, MD
Hematology & Oncology · Woonsocket, RINPI 1952332041
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Rigel Pharmaceuticals, Inc. at 41.4% of the total. Reporting peaked in 2022 at $19,343 and has fallen 73.4% since, to $5,137 in 2025. Among hematology & oncology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 571 payments — averaging $92.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$22K
- AstraZeneca$5K
- Incyte Corporation$3K
- Sirtex Medical Inc$3K
- Beone Medicines USA, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $17K from 54 others
What the payments were for
- Consulting fees$18,50635%
- Speaking & faculty fees$14,63628%
- Travel & lodging$1,4213%
- Food & beverage$16,82732%
- Education$1,4403%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,829 in reported general payments places this provider in the 90th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 17 | $356,111 |
| IbrancePalbociclib | 16 | $229,063 |
| VenclextaVenetoclax | 18 | $205,846 |
| JakafiRuxolitinib Phosphate | 11 | $192,659 |
| XtandiEnzalutamide | 14 | $94,709 |
| EliquisApixaban | 14 | $13,200 |
| Enoxaparin Sodium | 14 | $3,366 |
| Hydroxyurea | 53 | $944 |
| Ondansetron Hcl | 37 | $737 |
| Oxycodone Hcl | 40 | $687 |
| Letrozole | 37 | $669 |
| Anastrozole | 41 | $440 |
| Dexamethasone | 14 | $322 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $294 |
| Omeprazole | 18 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $516 | $356,11117 claims |
| PfizerIbrance, Eliquis | $443 | $242,26330 claims |
| AbbVieVenclexta | $689 | $205,84618 claims |
| Incyte CorporationJakafi | $3,350 | $192,65911 claims |
| Astellas Pharma US IncXtandi | $580 | $94,70914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 hematology & oncology providers in Rhode Island.
Other hematology & oncology in Woonsocket
- David StollWoonsocket$154
- Gerald ColvinWakefield$233K
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.